Ellipses Pharma
↗London, United Kingdom
Ellipses Pharma is a London-based oncology-focused drug development company founded in 2018 by Professor Sir Chris Evans and Dr Rajan Jethwa. The company specializes in accelerating the development of cancer treatments through an innovative drug development model that combines unbiased vetting to de-risk initial asset selection with an uninterrupted funding flow to minimize the time required to advance lead products through clinical trials. Rather than raising capital in traditional series-based rounds, Ellipses operates with permanent fixed funding sources that allow capital allocation as needed. The company serves as an incubator and accelerator for oncology assets, sourcing treatments from academia, biotech firms, and pharmaceutical partners, then advancing them through clinical development before out-licensing at appropriate stages. Ellipses has built a significant global presence with clinical trial sites across the US, Europe, and the Middle East.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2018
Ownership:private
Status:operating
FUNDING
Stage:Growth
Total Raised:$151M
Investors:Mohamed bin Zayed (President of the United Arab Emirates), Steve Morgan (founder of Redrow), Ronnie Wood, West Coast Capital, Sir Tom Hunter
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 2 (EP0031/A400)
Modalities:Small molecule kinase inhibitors, Monoclonal antibodies, Bifunctional proteins, Cell therapies, Bispecific antibodies
Active Trials:13
Trial Phases:Phase 1: 7 | Phase 2: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Sichuan Kelun-Biotech (A400/EP0031 licensing - Asia-Pacific rights retained by Kelun), SunRock Biopharma (EP0017 licensing - HER3:TRAIL fusion protein), Genome & Company (GENA-104/EP0089 licensing - checkpoint inhibitor), Academic institutions and research bodies (unspecified partnership network), Sarah Cannon Research Institute (clinical trial collaboration)
COMPETITION
Position:Emerging
Competitors:Eli Lilly (selpercatinib - first-generation RET inhibitor, approved), Roche/Blueprint Medicines (pralsetinib - first-generation RET inhibitor, approved), Merck, BMS, AstraZeneca, Pfizer, Regeneron, GSK (competing in immuno-oncology space), Other emerging RET inhibitor developers
LEADERSHIP
Key Executives:
Dr Rajan Jethwa - Chief Executive Officer & Founder
Professor Sir Chris Evans - Co-Founder & Chairman
David Cook - Chief Financial Officer & Director
Professor Tobias Arkenau - Chief Medical Officer & Global Head of Drug Development
Suzanne Wood - Chief HR Officer
Nicky Pattrick - Chief Business Development Officer
Luke Slatford - Director of Operations
Scientific Founders:Professor Sir Chris Evans
Board Members:Dr Rajan Jethwa (CEO, Founder), David Cook (CFO, Director)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Ellipses Pharma. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.